Genetic or pharmacological inhibition of IL-6, IL-8, and IL-11 or downstream mediators in models of bone metastases significantly decreases tumor growth and survival and osteolysis and prolongs survival of tumor-bearing mice [121,163,181,185,196,197,198], highlighting the importance of these mediators in cancer metastasis to bone. This evidence concerns the gene IL6 and neoplasm.